APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Huntington Disease Medications

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Huntington Disease Medications Market Outlook and Growth Opportunities 2026

Report ID 174000270429 December 2025190 pages

Choose your research edition.

Industry ResearchHuntington Disease Medications Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Huntington Disease Medications Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Huntington Disease Medications Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Huntington Disease Medications Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Huntington Disease Medications Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Huntington Disease Medications market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Huntington Disease Medications is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Huntington Disease Medications is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Huntington Disease Medications is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Huntington Disease Medications market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Huntington Disease Medications market include Teva, Sandoz, Mylan, Zydus, Sun Pharmaceutical, Neurocrine Biosciences, Lupin, Hetero and Dr. Reddy's Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Huntington Disease Medications market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Huntington Disease Medications and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Huntington Disease Medications sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Huntington Disease Medications market size, projected growth trends, production technologies, key applications, and end-use industries.

Huntington Disease Medications Segment by Company

Teva

Sandoz

Mylan

Zydus

Sun Pharmaceutical

Neurocrine Biosciences

Lupin

Hetero

Dr. Reddy's Laboratories

Chartwell Pharmaceuticals

Bionpharma

Bausch Health

Apotex

Actavis Laboratories

Huntington Disease Medications Segment by Type

Deutetrabenazine

Tetrabenazine

Valbenazine

Others

Huntington Disease Medications Segment by Application

Hospital and Clinic

Pharmacy

Other

Huntington Disease Medications Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Huntington Disease Medications status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Huntington Disease Medications market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Huntington Disease Medications significant trends, drivers, influence factors in global and regions.

6. To analyze Huntington Disease Medications competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Huntington Disease Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Huntington Disease Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Huntington Disease Medications.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Huntington Disease Medications market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Huntington Disease Medications industry.

Chapter 3: Detailed analysis of Huntington Disease Medications manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Huntington Disease Medications in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Huntington Disease Medications in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Huntington Disease Medications Industry Trends Table 2. Huntington Disease Medications Industry Drivers Table 3. Huntington Disease Medications Industry Opportunities and Challenges Table 4. Huntington Disease Medications Industry Restraints Table 5. Global Huntington Disease Medications Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Huntington Disease Medications Revenue Share by Company (2021-2026) Table 7. Global Huntington Disease Medications Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Huntington Disease Medications Sales Volume Share by Company (2021-2026) Table 9. Global Huntington Disease Medications Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Huntington Disease Medications Company Ranking, (2024-2026) & (USD Million) Table 11. Global Huntington Disease Medications Key Company Manufacturing Base & Headquarters Table 12. Global Huntington Disease Medications Company, Product Type & Application Table 13. Global Huntington Disease Medications Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Huntington Disease Medications by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Deutetrabenazine Table 18. Significant Companies of Tetrabenazine Table 19. Significant Companies of Valbenazine Table 20. Significant Companies of Others Table 21. Global Huntington Disease Medications Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Huntington Disease Medications Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Huntington Disease Medications Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Huntington Disease Medications Sales Volume Share by Type (2021-2026) Table 25. Global Huntington Disease Medications Sales Volume Share by Type (2027-2032) Table 26. Global Huntington Disease Medications Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Huntington Disease Medications Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Huntington Disease Medications Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Huntington Disease Medications Sales Value Share by Type (2021-2026) Table 30. Global Huntington Disease Medications Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital and Clinic Table 32. Significant Companies of Pharmacy Table 33. Significant Companies of Other Table 34. Global Huntington Disease Medications Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Huntington Disease Medications Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Huntington Disease Medications Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Huntington Disease Medications Sales Volume Share by Application (2021-2026) Table 38. Global Huntington Disease Medications Sales Volume Share by Application (2027-2032) Table 39. Global Huntington Disease Medications Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Huntington Disease Medications Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Huntington Disease Medications Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Huntington Disease Medications Sales Value Share by Application (2021-2026) Table 43. Global Huntington Disease Medications Sales Value Share by Application (2027-2032) Table 44. Global Huntington Disease Medications Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Huntington Disease Medications Sales by Region (2021-2026) & (K Units) Table 46. Global Huntington Disease Medications Sales Market Share by Region (2021-2026) Table 47. Global Huntington Disease Medications Sales by Region (2027-2032) & (K Units) Table 48. Global Huntington Disease Medications Sales Market Share by Region (2027-2032) Table 49. Global Huntington Disease Medications Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Huntington Disease Medications Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Huntington Disease Medications Sales Value Share by Region (2021-2026) Table 52. Global Huntington Disease Medications Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Huntington Disease Medications Sales Value Share by Region (2027-2032) Table 54. Global Huntington Disease Medications Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Huntington Disease Medications Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Huntington Disease Medications Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Huntington Disease Medications Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Huntington Disease Medications Sales by Country (2021-2026) & (K Units) Table 59. Global Huntington Disease Medications Sales Market Share by Country (2021-2026) Table 60. Global Huntington Disease Medications Sales by Country (2027-2032) & (K Units) Table 61. Global Huntington Disease Medications Sales Market Share by Country (2027-2032) Table 62. Global Huntington Disease Medications Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Huntington Disease Medications Sales Value Market Share by Country (2021-2026) Table 64. Global Huntington Disease Medications Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Huntington Disease Medications Sales Value Market Share by Country (2027-2032) Table 66. Teva Company Information Table 67. Teva Business Overview Table 68. Teva Huntington Disease Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Teva Huntington Disease Medications Product Portfolio Table 70. Teva Recent Development Table 71. Sandoz Company Information Table 72. Sandoz Business Overview Table 73. Sandoz Huntington Disease Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Sandoz Huntington Disease Medications Product Portfolio Table 75. Sandoz Recent Development Table 76. Mylan Company Information Table 77. Mylan Business Overview Table 78. Mylan Huntington Disease Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Mylan Huntington Disease Medications Product Portfolio Table 80. Mylan Recent Development Table 81. Zydus Company Information Table 82. Zydus Business Overview Table 83. Zydus Huntington Disease Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Zydus Huntington Disease Medications Product Portfolio Table 85. Zydus Recent Development Table 86. Sun Pharmaceutical Company Information Table 87. Sun Pharmaceutical Business Overview Table 88. Sun Pharmaceutical Huntington Disease Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Sun Pharmaceutical Huntington Disease Medications Product Portfolio Table 90. Sun Pharmaceutical Recent Development Table 91. Neurocrine Biosciences Company Information Table 92. Neurocrine Biosciences Business Overview Table 93. Neurocrine Biosciences Huntington Disease Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Neurocrine Biosciences Huntington Disease Medications Product Portfolio Table 95. Neurocrine Biosciences Recent Development Table 96. Lupin Company Information Table 97. Lupin Business Overview Table 98. Lupin Huntington Disease Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Lupin Huntington Disease Medications Product Portfolio Table 100. Lupin Recent Development Table 101. Hetero Company Information Table 102. Hetero Business Overview Table 103. Hetero Huntington Disease Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Hetero Huntington Disease Medications Product Portfolio Table 105. Hetero Recent Development Table 106. Dr. Reddy's Laboratories Company Information Table 107. Dr. Reddy's Laboratories Business Overview Table 108. Dr. Reddy's Laboratories Huntington Disease Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Dr. Reddy's Laboratories Huntington Disease Medications Product Portfolio Table 110. Dr. Reddy's Laboratories Recent Development Table 111. Chartwell Pharmaceuticals Company Information Table 112. Chartwell Pharmaceuticals Business Overview Table 113. Chartwell Pharmaceuticals Huntington Disease Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Chartwell Pharmaceuticals Huntington Disease Medications Product Portfolio Table 115. Chartwell Pharmaceuticals Recent Development Table 116. Bionpharma Company Information Table 117. Bionpharma Business Overview Table 118. Bionpharma Huntington Disease Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Bionpharma Huntington Disease Medications Product Portfolio Table 120. Bionpharma Recent Development Table 121. Bausch Health Company Information Table 122. Bausch Health Business Overview Table 123. Bausch Health Huntington Disease Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Bausch Health Huntington Disease Medications Product Portfolio Table 125. Bausch Health Recent Development Table 126. Apotex Company Information Table 127. Apotex Business Overview Table 128. Apotex Huntington Disease Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Apotex Huntington Disease Medications Product Portfolio Table 130. Apotex Recent Development Table 131. Actavis Laboratories Company Information Table 132. Actavis Laboratories Business Overview Table 133. Actavis Laboratories Huntington Disease Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Actavis Laboratories Huntington Disease Medications Product Portfolio Table 135. Actavis Laboratories Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Huntington Disease Medications Distributors List Table 139. Huntington Disease Medications Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Huntington Disease Medications Product Image Figure 2. Global Huntington Disease Medications Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Huntington Disease Medications Sales Value (2021-2032) & (US$ Million) Figure 4. Global Huntington Disease Medications Sales (2021-2032) & (K Units) Figure 5. Global Huntington Disease Medications Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Huntington Disease Medications Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Deutetrabenazine Image Figure 10. Tetrabenazine Image Figure 11. Valbenazine Image Figure 12. Others Image Figure 13. Global Huntington Disease Medications Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Huntington Disease Medications Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Huntington Disease Medications Sales Volume Share by Type (2021-2032) Figure 16. Global Huntington Disease Medications Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Huntington Disease Medications Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Huntington Disease Medications Sales Value Share by Type (2021-2032) Figure 19. Hospital and Clinic Image Figure 20. Pharmacy Image Figure 21. Other Image Figure 22. Global Huntington Disease Medications Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Huntington Disease Medications Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Huntington Disease Medications Sales Volume Share by Application (2021-2032) Figure 25. Global Huntington Disease Medications Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Huntington Disease Medications Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Huntington Disease Medications Sales Value Share by Application (2021-2032) Figure 28. Global Huntington Disease Medications Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Huntington Disease Medications Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Huntington Disease Medications Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Huntington Disease Medications Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Huntington Disease Medications Sales Value (2021-2032) & (US$ Million) Figure 33. North America Huntington Disease Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Huntington Disease Medications Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Huntington Disease Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Huntington Disease Medications Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Huntington Disease Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Huntington Disease Medications Sales Value (2021-2032) & (US$ Million) Figure 39. South America Huntington Disease Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Huntington Disease Medications Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Huntington Disease Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Huntington Disease Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Huntington Disease Medications Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Huntington Disease Medications Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Deutetrabenazine
  • Tetrabenazine
  • Valbenazine
  • Others
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Teva
  • Sandoz
  • Mylan
  • Zydus
  • Sun Pharmaceutical
  • Neurocrine Biosciences
  • Lupin
  • Hetero
  • Dr. Reddy's Laboratories
  • Chartwell Pharmaceuticals
  • Bionpharma
  • Bausch Health
  • Apotex
  • Actavis Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Huntington Disease Medications Sales Value (2021-2032)
  4. 1.2.2 Global Huntington Disease Medications Sales Volume (2021-2032)
  5. 1.2.3 Global Huntington Disease Medications Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Huntington Disease Medications Market Dynamics
  1. 2.1 Huntington Disease Medications Industry Trends
  2. 2.2 Huntington Disease Medications Industry Drivers
  3. 2.3 Huntington Disease Medications Industry Opportunities and Challenges
  4. 2.4 Huntington Disease Medications Industry Restraints
3 Huntington Disease Medications Market by Company
  1. 3.1 Global Huntington Disease Medications Company Revenue Ranking in 2025
  2. 3.2 Global Huntington Disease Medications Revenue by Company (2021-2026)
  3. 3.3 Global Huntington Disease Medications Sales Volume by Company (2021-2026)
  4. 3.4 Global Huntington Disease Medications Average Price by Company (2021-2026)
  5. 3.5 Global Huntington Disease Medications Company Ranking (2024-2026)
  6. 3.6 Global Huntington Disease Medications Company Manufacturing Base and Headquarters
  7. 3.7 Global Huntington Disease Medications Company Product Type and Application
  8. 3.8 Global Huntington Disease Medications Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Huntington Disease Medications Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Huntington Disease Medications Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Huntington Disease Medications Market by Type
  1. 4.1 Huntington Disease Medications Type Introduction
  2. 4.1.1 Deutetrabenazine
  3. 4.1.2 Tetrabenazine
  4. 4.1.3 Valbenazine
  5. 4.1.4 Others
  6. 4.2 Global Huntington Disease Medications Sales Volume by Type
  7. 4.2.1 Global Huntington Disease Medications Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Huntington Disease Medications Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Huntington Disease Medications Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Huntington Disease Medications Sales Value by Type
  11. 4.3.1 Global Huntington Disease Medications Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Huntington Disease Medications Sales Value by Type (2021-2032)
  13. 4.3.3 Global Huntington Disease Medications Sales Value Share by Type (2021-2032)
5 Huntington Disease Medications Market by Application
  1. 5.1 Huntington Disease Medications Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Huntington Disease Medications Sales Volume by Application
  6. 5.2.1 Global Huntington Disease Medications Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Huntington Disease Medications Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Huntington Disease Medications Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Huntington Disease Medications Sales Value by Application
  10. 5.3.1 Global Huntington Disease Medications Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Huntington Disease Medications Sales Value by Application (2021-2032)
  12. 5.3.3 Global Huntington Disease Medications Sales Value Share by Application (2021-2032)
6 Huntington Disease Medications Regional Sales and Value Analysis
  1. 6.1 Global Huntington Disease Medications Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Huntington Disease Medications Sales by Region (2021-2032)
  3. 6.2.1 Global Huntington Disease Medications Sales by Region: 2021-2026
  4. 6.2.2 Global Huntington Disease Medications Sales by Region (2027-2032)
  5. 6.3 Global Huntington Disease Medications Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Huntington Disease Medications Sales Value by Region (2021-2032)
  7. 6.4.1 Global Huntington Disease Medications Sales Value by Region: 2021-2026
  8. 6.4.2 Global Huntington Disease Medications Sales Value by Region (2027-2032)
  9. 6.5 Global Huntington Disease Medications Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Huntington Disease Medications Sales Value (2021-2032)
  12. 6.6.2 North America Huntington Disease Medications Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Huntington Disease Medications Sales Value (2021-2032)
  15. 6.7.2 Europe Huntington Disease Medications Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Huntington Disease Medications Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Huntington Disease Medications Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Huntington Disease Medications Sales Value (2021-2032)
  21. 6.9.2 South America Huntington Disease Medications Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Huntington Disease Medications Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Huntington Disease Medications Sales Value Share by Country, 2025 VS 2032
7 Huntington Disease Medications Country-level Sales and Value Analysis
  1. 7.1 Global Huntington Disease Medications Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Huntington Disease Medications Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Huntington Disease Medications Sales by Country (2021-2032)
  4. 7.3.1 Global Huntington Disease Medications Sales by Country (2021-2026)
  5. 7.3.2 Global Huntington Disease Medications Sales by Country (2027-2032)
  6. 7.4 Global Huntington Disease Medications Sales Value by Country (2021-2032)
  7. 7.4.1 Global Huntington Disease Medications Sales Value by Country (2021-2026)
  8. 7.4.2 Global Huntington Disease Medications Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Huntington Disease Medications Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Huntington Disease Medications Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Huntington Disease Medications Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Huntington Disease Medications Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Huntington Disease Medications Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Sandoz
  8. 8.2.1 Sandoz Company Information
  9. 8.2.2 Sandoz Business Overview
  10. 8.2.3 Sandoz Huntington Disease Medications Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sandoz Huntington Disease Medications Product Portfolio
  12. 8.2.5 Sandoz Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan Huntington Disease Medications Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Huntington Disease Medications Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 Zydus
  20. 8.4.1 Zydus Company Information
  21. 8.4.2 Zydus Business Overview
  22. 8.4.3 Zydus Huntington Disease Medications Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Zydus Huntington Disease Medications Product Portfolio
  24. 8.4.5 Zydus Recent Developments
  25. 8.5 Sun Pharmaceutical
  26. 8.5.1 Sun Pharmaceutical Company Information
  27. 8.5.2 Sun Pharmaceutical Business Overview
  28. 8.5.3 Sun Pharmaceutical Huntington Disease Medications Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sun Pharmaceutical Huntington Disease Medications Product Portfolio
  30. 8.5.5 Sun Pharmaceutical Recent Developments
  31. 8.6 Neurocrine Biosciences
  32. 8.6.1 Neurocrine Biosciences Company Information
  33. 8.6.2 Neurocrine Biosciences Business Overview
  34. 8.6.3 Neurocrine Biosciences Huntington Disease Medications Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Neurocrine Biosciences Huntington Disease Medications Product Portfolio
  36. 8.6.5 Neurocrine Biosciences Recent Developments
  37. 8.7 Lupin
  38. 8.7.1 Lupin Company Information
  39. 8.7.2 Lupin Business Overview
  40. 8.7.3 Lupin Huntington Disease Medications Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Lupin Huntington Disease Medications Product Portfolio
  42. 8.7.5 Lupin Recent Developments
  43. 8.8 Hetero
  44. 8.8.1 Hetero Company Information
  45. 8.8.2 Hetero Business Overview
  46. 8.8.3 Hetero Huntington Disease Medications Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hetero Huntington Disease Medications Product Portfolio
  48. 8.8.5 Hetero Recent Developments
  49. 8.9 Dr. Reddy's Laboratories
  50. 8.9.1 Dr. Reddy's Laboratories Company Information
  51. 8.9.2 Dr. Reddy's Laboratories Business Overview
  52. 8.9.3 Dr. Reddy's Laboratories Huntington Disease Medications Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Dr. Reddy's Laboratories Huntington Disease Medications Product Portfolio
  54. 8.9.5 Dr. Reddy's Laboratories Recent Developments
  55. 8.10 Chartwell Pharmaceuticals
  56. 8.10.1 Chartwell Pharmaceuticals Company Information
  57. 8.10.2 Chartwell Pharmaceuticals Business Overview
  58. 8.10.3 Chartwell Pharmaceuticals Huntington Disease Medications Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Chartwell Pharmaceuticals Huntington Disease Medications Product Portfolio
  60. 8.10.5 Chartwell Pharmaceuticals Recent Developments
  61. 8.11 Bionpharma
  62. 8.11.1 Bionpharma Company Information
  63. 8.11.2 Bionpharma Business Overview
  64. 8.11.3 Bionpharma Huntington Disease Medications Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Bionpharma Huntington Disease Medications Product Portfolio
  66. 8.11.5 Bionpharma Recent Developments
  67. 8.12 Bausch Health
  68. 8.12.1 Bausch Health Company Information
  69. 8.12.2 Bausch Health Business Overview
  70. 8.12.3 Bausch Health Huntington Disease Medications Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Bausch Health Huntington Disease Medications Product Portfolio
  72. 8.12.5 Bausch Health Recent Developments
  73. 8.13 Apotex
  74. 8.13.1 Apotex Company Information
  75. 8.13.2 Apotex Business Overview
  76. 8.13.3 Apotex Huntington Disease Medications Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Apotex Huntington Disease Medications Product Portfolio
  78. 8.13.5 Apotex Recent Developments
  79. 8.14 Actavis Laboratories
  80. 8.14.1 Actavis Laboratories Company Information
  81. 8.14.2 Actavis Laboratories Business Overview
  82. 8.14.3 Actavis Laboratories Huntington Disease Medications Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Actavis Laboratories Huntington Disease Medications Product Portfolio
  84. 8.14.5 Actavis Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Huntington Disease Medications Value Chain Analysis
  2. 9.1.1 Huntington Disease Medications Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Huntington Disease Medications Sales Mode & Process
  6. 9.2 Huntington Disease Medications Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Huntington Disease Medications Distributors
  9. 9.2.3 Huntington Disease Medications Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst